CA
NVAX icon

Clearstead Advisors’s Novavax NVAX Stock Holding History

Clearstead Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$915 Buy
+97
New +$869 ﹤0.01% 2727
2021
Q3 		– Sell
-265
Closed -$56K – 1354
2021
Q2 		$56K Buy
265
+157
+145% +$28.8K ﹤0.01% 536
2021
Q1 		$20K Hold
108
– – ﹤0.01% 681
2020
Q4 		$12K Hold
108
– – ﹤0.01% 697
2020
Q3 		$12K Buy
+108
New +$13.2K ﹤0.01% 645

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Clearstead Advisors's NVAX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Novavax (NVAX) in Q2 2026: 97 shares worth $915. The stake represents ﹤0.01% of the portfolio and ranks #2727 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in NVAX as recently as Q2 2021.

Clearstead Advisors first reported a position in NVAX in Q3 2020 and has held it in 5 quarters since. The position peaked at $56K in Q2 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Clearstead Advisors held 97 shares of Novavax worth $915 as of Q2 2026.
  • Novavax was a new Clearstead Advisors position in Q2 2026.
  • Novavax made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2727 holding.
  • Clearstead Advisors first reported a position in Novavax in Q3 2020 and has held it in 5 quarters since.
  • Clearstead Advisors's Novavax position peaked at $56K in Q2 2021.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.